Page 1

EP Edwards FOR IMMEDIATE RELEASE Media Contact : Sarah Huoh , 949-250-5070 Investor Contact : Mark Wilterding , 949-250-6826 Edwards Lifesciences Corporation One Edwards Way Irvine , CA USA 92614 Phone : 949.250.2500 Fax : 949.250.2525 www.edwards.com EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS IRVINE , Calif . , April 20 , 2021. - Edwards Lifesciences ( NYSE : EW ) today reported financial results for the quarter ended March 31 , 2021 . First Quarter Highlights and 2021 Outlook • Sales grew 8 percent to $ 1.2 billion ; underlying¹ sales grew 5 percent • TAVR sales grew 7 percent ; underlying sales grew 4 percent • EPS of $ 0.54 exceeded expectations ● Received approval for a U.S. pivotal trial for TAVR in moderate AS patients Received TAVR approval in Japan for patients at low surgical risk • First patients were treated with EVOQUE Eos transcatheter mitral replacement system Initiated TRISCEND II U.S. pivotal trial for transcatheter tricuspid replacement Completed Accelerated Share Repurchase Continued confidence in sales outlook ; Adjusted EPS guidance of $ 2.07 to $ 2.27 increased $ 0.07 " We recognize that there are many people still struggling with the pandemic around the world , yet as we anniversary the start of the pandemic , I'm encouraged by the signs of recovery , " said Michael A. Mussallem , chairman and CEO . " Structural heart procedures increased as we progressed through the winter months , and our sales growth this quarter was better - than - expected . Although we anticipate the effects of the pandemic will impact structural heart patients in the near term , we have continued confidence in our positive 2021 outlook . " First Quarter 2021 Results Sales for the quarter ended March 31 , 2021 were $ 1.2 billion , up 8 percent over the prior year , or 5 percent on an underlying basis . Diluted earnings per share for the quarter were $ 0.54 . Transcatheter Aortic Valve Replacement ( TAVR ) For the quarter , the company reported global TAVR sales of $ 792 million , a year - over - year increase of 7 percent on a reported basis and 4 percent on an underlying basis . The SAPIEN 3 Ultra platform continues to be differentiated with low complication rates , as well as ease - of - use , and significant potential for length - of - stay efficiency . Earlier this month , the company received approval to begin treating